NCT00055419 - A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer | Biotech Hunter

Enrollment

744

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

July 31, 2004

Study Completion Date

August 31, 2004

Conditions

Colorectal Neoplasms

Interventions

BIOLOGICAL

Cetuximab

400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression

Trial Locations (29)

10016

ImClone Investigational Site, New York

11733

ImClone Investigational Site, East Setauket

12110

ImClone Investigational Site, Latham

20057

ImClone Investigational Site, Washington D.C.

21204

ImClone Investigational Site, Baltimore

23502

ImClone Investigational Site, Norfolk

29605

ImClone Investigational Site, Greenville

30318

ImClone Investigational Site, Atlanta

32207

ImClone Investigational Site, Jacksonville

32804

ImClone Investigational Site, Orlando

33176

ImClone Investigational Site, Miami

38104

ImClone Investigational Site, Memphis

40202

ImClone Investigational Site, Louisville

44134

ImClone Investigational Site, Cleveland

48198

ImClone Investigational Site, Ypsilanti

54307

ImClone Investigational Site, Green Bay

55416

ImClone Investigational Site, Minneapolis

59405

ImClone Investigational Site, Great Falls

62526

ImClone Investigational Site, Decatur

63301

ImClone Investigational Site, Saint Charles

70121

ImClone Investigational Site, New Orleans

75230

ImClone Investigational Site, Dallas

80218

ImClone Investigational Site, Denver

89109

ImClone Investigational Site, Las Vegas

90025

ImClone Investigational Site, Los Angeles

93309

ImClone Investigational Site, Bakersfield

97239

ImClone Investigational Site, Portland

06790

ImClone Investigational Site, Torrington

08043

ImClone Investigational Site, Voorhees Township